JAMES KRANTZ: Open Payments
NPI 1801992029 · THURMONT, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,204 in 50 payments from 15 companies in 2025. Trend: 2023 $2,505 · 2024 $2,376 · 2025 $1,204
Food & beverage: $1,204
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $229 |
| AstraZeneca Pharmaceuticals LP | 9 | $215 |
| Lilly USA, LLC | 6 | $154 |
| Amgen Inc. | 8 | $137 |
| GlaxoSmithKline, LLC. | 4 | $86 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| ABBVIE INC. | 2 | $43 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
Products named: AIRSUPRA, Wegovy, JARDIANCE, EVENITY, MOUNJARO, CAPLYTA, TRELEGY ELLIPTA, FARXIGA.
Industry payments across MD — which companies pay providers there.
